A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Condition(s) studied
Investigational drug(s) / intervention(s)
Bimagrumab: Administered SC
Tirzepatide: Administered SC
Bimagrumab Placebo: Administered SC
Tirzepatide Placebo: Administered SC
Study summary
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Eligibility
Primary outcome measure(s)
- Percent Change from Baseline in Body Weight — Baseline, Week 24
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| Pinnacle Research Group, LLC | Anniston | Alabama | |
| Central Research Associates | Birmingham | Alabama | |
| Diablo Clinical Research, Inc. | Walnut Creek | California | |
| Clinical Neuroscience Solutions, Inc. dba CNS Healthcare | Jacksonville | Florida | |
| Altus Research | Lake Worth | Florida | |
| Suncoast Research Group | Miami | Florida | |
| East-West Medical Research Institute | Honolulu | Hawaii | |
| Great Lakes Clinical Trials - Ravenswood | Chicago | Illinois | |
| SKY Integrative Medical Center/SKYCRNG | Ridgeland | Mississippi | |
| Keystone Clinical Studies | Plymouth Meeting | Pennsylvania | |
| Eastside Research Associates | Redmond | Washington | |
| Rainier Clinical Research Center | Renton | Washington |
On this site
📄 Mounjaro (tirzepatide) drug profile →More Eli Lilly and Company trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06643728 on ClinicalTrials.gov ↗ ← All trials in the USA